{
    "clinical_study": {
        "@rank": "147840", 
        "arm_group": [
            {
                "arm_group_label": "Kovacaine Mist, 3 sprays unilateral", 
                "arm_group_type": "Experimental", 
                "description": "Tetracaine HCl 3% and Oxymetazoline HCl 0.05%"
            }, 
            {
                "arm_group_label": "Tetracaine Only, 3 sprays unilateral", 
                "arm_group_type": "Experimental", 
                "description": "Tetracaine HCl 3%"
            }, 
            {
                "arm_group_label": "Placebo, 3 sprays unilateral", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the efficacy of Kovacaine Mist, Tetracaine only, and\n      Placebo for inducing pulpal anesthesia of the maxillary teeth in adults."
        }, 
        "brief_title": "Comparison of Intranasal Kovacaine Mist, Tetracaine Alone, and Placebo for Anesthetizing Maxillary Teeth in Adults", 
        "completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "condition": "Anesthesia", 
        "detailed_description": {
            "textblock": "The study will employ a multi-center, randomized, double-blind, placebo-controlled,\n      parallel-groups design to assess the safety and efficacy of Kovacaine Mist delivered\n      intranasally for inducing pulpal anesthesia of maxillary teeth numbers 4 to 13 (maxillary\n      right second premolar to maxillary left second premolar) sufficient to allow completion of\n      the Study Dental Procedure.\n\n      The intent is to treat 110 subjects, with enrollment balanced evenly between the 2 study\n      sites, 2:2:1 randomization within each study site and an overall goal of 44 subjects treated\n      with Kovacaine Mist, 44 treated with Tetracaine alone, and 22 treated with Placebo.\n      Recruitment will be from diverse dental patient populations."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female 18 years of age or older.\n\n          -  Need for an operative restorative dental procedure requiring local anesthesia for a\n             single vital maxillary tooth (other than a maxillary first, second, or third molar)\n             with no evidence of pulpal pathology.\n\n          -  Normal lip, nose, eyelid, and cheek sensation.\n\n          -  Able to understand and sign the study informed consent document, communicate with the\n             investigators, and understand and comply with the requirements of the protocol.\n\n          -  Patency of the naris ipsilateral to the tooth undergoing the Study Dental Procedure.\n\n          -  Resting heart rate (HR) between 55 and 100 beats per minute (bpm), inclusive.\n\n          -  Seated systolic blood pressure (SBP) between 95 and 140 mm Hg, inclusive and seated\n             diastolic blood pressure (DBP) between 60 and 90 mm Hg, inclusive.\n\n        Exclusion Criteria:\n\n          -  Inadequately controlled hypertension (blood pressure greater than 140/90 mm Hg).\n\n          -  Inadequately controlled active thyroid disease of any type.\n\n          -  Frequent nose bleeds (\u2265 5 per month).\n\n          -  Having received dental care requiring a local anesthetic within the last 24 hours.\n\n          -  History of allergy to or intolerance of tetracaine, benzyl alcohol, other ester local\n             anesthetics, or para-aminobenzoic acid (as found in PABA-containing sunscreen).\n\n          -  History of allergy or hypersensitivity to articaine, oxymetazoline, epinephrine, or\n             sulfite preservatives.\n\n          -  Use of a monoamine oxidase inhibitor within the 3 weeks preceding study entry.\n\n          -  Nursing, pregnant, suspected of being pregnant, or trying to become pregnant.\n             (Females of child-bearing potential will be required to take a urine pregnancy test\n             on the day of, but prior to, study drug administration to rule out pregnancy.)\n\n          -  Having received any investigational drug and/or participation in any clinical trial\n             within 30 days prior to study participation.\n\n          -  Having used oxymetazoline or phenylephrine nasal spray, nasal irrigation, or other\n             nasal or oral decongestant on the day of the study procedure.\n\n          -  History of congenital or idiopathic methemoglobinemia"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "110", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01710787", 
            "org_study_id": "SR 3-02"
        }, 
        "intervention": [
            {
                "arm_group_label": "Kovacaine Mist, 3 sprays unilateral", 
                "description": "3 unilateral intranasal sprays per dose", 
                "intervention_name": "Tetracaine HCl 3% and Oxymetazoline HCl 0.05%", 
                "intervention_type": "Drug", 
                "other_name": "Kovacaine Mist"
            }, 
            {
                "arm_group_label": "Tetracaine Only, 3 sprays unilateral", 
                "description": "3 unilateral intranasal sprays per dose", 
                "intervention_name": "Tetracaine HCl 3%", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo, 3 sprays unilateral", 
                "description": "3 unilateral intranasal sprays per dose", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Tetracaine", 
                "Oxymetazoline", 
                "Phenylephrine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "operative", 
            "dental procedure"
        ], 
        "lastchanged_date": "February 19, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Buffalo", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "University of Buffalo"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84124"
                    }, 
                    "name": "Family and Cosmetic Dentistry"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84124"
                    }, 
                    "name": "Jean Brown Research"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase III, Multi-Center, Randomized, Double-Blind, Parallel-Groups Clinical Trial Comparing the Efficacy and Safety of Intranasally Administered Kovacaine Mist to Tetracaine Alone and to Placebo for Anesthetizing Maxillary Teeth in Adults", 
        "overall_official": {
            "affiliation": "University of Pittsburgh", 
            "last_name": "Paul A. Moore, DMD/PhD/MPH", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Completion of the Study Dental Procedure without need for rescue by injection of local anesthetic (yes/no).", 
            "safety_issue": "No", 
            "time_frame": "at 15 minutes with a 3 minute window"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01710787"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Intraoral soft-tissue anesthesia (yes/no) and the time to onset and duration of such soft-tissue anesthesia.", 
                "safety_issue": "No", 
                "time_frame": "at 15, 30, 45, 60, 90, and 120 minutes with a 3 minute window"
            }, 
            {
                "measure": "Heart Rate higher than 125 bpm", 
                "safety_issue": "Yes", 
                "time_frame": "at any time within 120 minutes following drug administration"
            }, 
            {
                "measure": "Heart Rate lower than 50 bpm", 
                "safety_issue": "Yes", 
                "time_frame": "at any time within 120 minutes following drug administration"
            }, 
            {
                "measure": "Increase from baseline in Systolic blood pressure greater than or equal to 25 mm Hg and to a value higher than 140 mm Hg", 
                "safety_issue": "Yes", 
                "time_frame": "at any time within 120 minutes following drug administration"
            }, 
            {
                "measure": "Decrease from baseline in Systolic blood pressure greater than or equal to 15 mm Hg and to a value lower than 90 mm Hg", 
                "safety_issue": "Yes", 
                "time_frame": "at any time within 120 minutes following drug administration"
            }, 
            {
                "measure": "Increase from baseline in Diastolic blood pressure greater than or equal to 15 mm Hg and to a value higher than 95 mm Hg", 
                "safety_issue": "Yes", 
                "time_frame": "at any time within 120 minutes following drug administration"
            }, 
            {
                "measure": "Decrease from baseline in Diastolic blood pressure greater than or equal to 10 mm Hg and to a value lower than 50 mm Hg", 
                "safety_issue": "Yes", 
                "time_frame": "at any time within 120 minutes following drug administration"
            }, 
            {
                "measure": "Maximum change from baseline in Heart Rate, Systolic blood pressure and Diastolic blood pressure", 
                "safety_issue": "Yes", 
                "time_frame": "from baseline to 120 minutes following drug administration"
            }, 
            {
                "measure": "The profile over time of Heart Rate, Systolic blood pressure and Diastolic blood pressure", 
                "safety_issue": "Yes", 
                "time_frame": "from baseline to 120 minutes following drug administratio"
            }, 
            {
                "measure": "Alcohol Sniff Test", 
                "safety_issue": "Yes", 
                "time_frame": "administered at approximately 24 hours after drug administration"
            }
        ], 
        "source": "St. Renatus, LLC", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Triligent International", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Tegra Analytics", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "St. Renatus, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}